Design, Synthesis, and Pharmacological Evaluation of Novel Hybrid Compounds To Treat Sickle Cell Disease Symptoms
Citations Over TimeTop 15% of 2011 papers
Abstract
A novel series of thalidomide derivatives (4a-f) designed by molecular hybridization were synthesized and evaluated in vitro and in vivo for their potential use in the oral treatment of sickle cell disease symptoms. Compounds 4a-f demonstrated analgesic, anti-inflammatory, and NO-donor properties. Compounds 4c and 4d were considered promising candidate drugs and were further evaluated in transgenic sickle cell mice to determine their capacity to reduce the levels of the proinflammatory cytokine tumor necrosis factor α (TNFα). Unlike hydroxyurea, the compounds reduced the concentrations of TNFα to levels similar to those induced with the control dexamethasone (300 μmol/kg). These compounds are novel lead drug candidates with multiple beneficial actions in the treatment of sickle cell disease symptoms and offer an alternative to hydroxyurea treatment.
Related Papers
- Therapeutic effect of small dose thalidomide and dexamethasone for old multiple myeloma(MM) patients(2009)
- Clinical observation on low dose thalidomide combined with the dexamethasone in treatment of multiple myeloma(2011)
- The Clinical Effectiveness Of Thalidomide Combined With Low Dose Dexamethasone On Multiple Myeloma(2010)
- Clinical Observation of the Combination of Thalidomide and Dexamethasone for the Treatmemt of Recurrent Multiple Myeloma(2009)
- Clinical observation on the thalidomide combined with the dexamethasone in treatment of multiple myeloma(2008)